Early warning biomarkers for Alzheimer's risk

An evidence-based look at Early warning biomarkers for Alzheimer's risk as part of our Neurodegeneration guide in Diseases of Aging. What the human research actually shows, the strongest mechanistic case, and what it means for healthspan.

Why this matters

This article sits inside our Neurodegeneration guide under Diseases of Aging. The longevity field moves fast and a lot of what gets shared online is mechanistic hand-waving. On ImmortalityLab we grade claims on the strength of human evidence, not marketing.

What the data actually shows

The strongest evidence here comes from a mix of randomised controlled trials, large prospective cohorts and mechanistic work in model organisms. In this piece we walk through the key papers, what they measured, and how robust the effect size is.

• Strength of evidence: graded by trial quality, sample size and replication.
• Mechanism: how this connects to the hallmarks of aging.
• Practical takeaway: what you can actually do with the information today.

Key takeaways

• The human evidence around "Early warning biomarkers for Alzheimer's risk" is reviewed in context, not in isolation.
• Mechanism is interesting, but human outcomes are the bar.
• No intervention in longevity is a silver bullet - stacked, consistent basics still win.

References

This is a seed article created for the initial build of the ImmortalityLab library. The cron-based content pipeline (see cron/generate_article.php) will fill in citations and deeper analysis over time.